Market Performance - On Tuesday, A-shares experienced a slight decline, with the Shanghai Composite Index falling by 0.18% to 3340.69 points, the Shenzhen Composite Index down by 0.29%, the ChiNext Index down by 0.35%, and the STAR 50 Index down by 0.95%. In contrast, the Northern Stock Exchange 50 Index rose by 0.08% [1] Monetary Policy - The central bank has been actively injecting liquidity into the market, conducting a 7-day reverse repurchase operation of 382 billion yuan on Monday, resulting in a net injection of 247 billion yuan after 135 billion yuan of reverse repos matured. On Tuesday, another operation of 448 billion yuan was conducted, leading to a net injection of 91 billion yuan after 357 billion yuan matured [2] Economic Indicators - The National Bureau of Statistics reported a 1.4% increase in profits for industrial enterprises above designated size from January to April, which is an improvement of 0.6 percentage points compared to the 0.8% growth from January to March. Specifically, profits in April rose by 3.0% year-on-year, surpassing the 2.6% increase in March. However, the profit data may be distorted due to significant export and import activities during the period of heightened US-China tariff discussions, leading to a muted market reaction [3] Market Outlook - Despite the generally favorable news, the impact on the market is expected to be limited. The market is likely to maintain a balanced and fluctuating pattern, with investors advised to hold their positions and observe [4]

Core Viewpoint - A-shares experienced a slight increase followed by a decline, with the gaming and controllable nuclear fusion sectors showing strength [1] Market Performance - The three major A-share indices opened slightly lower, with the Shanghai Composite Index rising nearly 0.5% at one point before retreating [1] - As of the midday session, the Shanghai Composite Index fell by 0.30%, the Shenzhen Component Index decreased by 0.71%, and the ChiNext Index dropped by 1.28% [1] - The North Star 50 Index saw a slight increase of 0.11% [1] Sector Performance - Leading sectors included gaming, controllable nuclear fusion, and airport shipping [1] - Underperforming sectors included chemical pharmaceuticals, CRO concepts, and complete automobiles [1] Trading Volume - Nearly 2,500 stocks declined across the two markets, with a total trading volume exceeding 640 billion yuan during the half-day session [1]

今天，A股三大指数午后集体回调。全市场成交额11826亿元，较上日增加429亿元。医药板块逆势走 强，CRO、减肥药、化学制药等方向领涨。 14:00左右， 多只沪深300ETF量能显著放大 。截至收盘，华泰柏瑞沪深300ETF成交额近34亿元，易方 达沪深300ETF、嘉实沪深300ETF成交额显著放量。 截至收盘，沪指跌0.94%，深证成指跌0.85%，创业板指跌1.18%。板块方面，可控核聚变、贵金属、创 新药、维生素等板块涨幅居前，港口、游戏、算力、电力等板块跌幅居前。 赛力斯全天成交额超100亿元 赛力斯涨停，全天成交额超100亿元。 关注" 新华网财经 "视频号 更多财经资讯等你来看 渤海证券称，长期来看，美国居高不下的债务和赤字率、潜在的再通胀风险、全球复杂的地缘局势以及 多国央行购金等因素均对金价形成支撑。当前宏观情绪缓和背景下需关注短期波动，而长期基本面利好 因素仍存，黄金具备战略配置价值。 知名黄金分析师Jordan Roy-Byrne认为，黄金价格在年底有可能达到3700美元/盎司。金价将在未来12个 月内达到4400美元至4500美元/盎司。此外，白银价格也将突破100美元/盎司。 （ ...

金十数据5月22日讯，三大指数今日低开，早盘震荡，午后加速下跌。截至收盘，沪指收跌0.94%，深 证成指收跌0.85%，创业板指收跌1.18%。盘面上，港口航运板块领跌，兵装重组概念、游戏股走低； 可控核聚变板块走强，贵金属板块午后冲高，CRO概念、医疗服务板块涨幅居前。赛力斯涨停，成交 额超106亿元。沪深两市成交额1.18万亿元，全市场超4200只个股下跌。 A股收评：创业板指收跌1.18% 全市场超4200只个股下跌 ...

Group 1: Market Overview - The Hang Seng Index rose by 0.58%, gaining 135 points to close at 23,679 points, while the Hang Seng Tech Index increased by 0.61% [1] - The early trading volume in Hong Kong stocks reached HKD 1,094 million [1] Group 2: CRO Sector Performance - CRO concept stocks led the gains, with Trump's drug pricing policy potentially benefiting the domestic CXO industry, as institutions noted a fundamental turning point has emerged [1] - Zhaoyan New Drug (603127) surged over 10%, while Tigermed (300347) rose by 13%, and Kanglong Chemical (300759) increased by 7% [1] - WuXi AppTec (603259) saw a rise of 2.76% [1] Group 3: Semiconductor and Technology Stocks - InnoCare (02577) increased by over 4%, following a significant rise of over 14% the previous day, driven by the collaboration between NVIDIA and Navitas, igniting a gallium nitride (GaN) trend [2] - Fourth Paradigm (06682) rose by 2.63%, with enterprise-level agent demand beginning to explode, indicating sustained high revenue growth for the company [5] Group 4: Biopharmaceuticals - Rongchang Biopharmaceutical (09995) increased by over 4%, with a cumulative rise of 2.5 times this year, as institutions noted that H-share placements have bolstered cash reserves [3] - Gilead Sciences-B (01672) rose by over 4% after its psoriasis treatment drug ASC50 received approval for Phase I clinical trials in the U.S. [8] Group 5: Music Streaming - NetEase Cloud Music (09899) rose by over 6%, reaching a new high, driven by operational leverage that improved gross margins, with institutions optimistic about the valuation increase in music streaming [4] Group 6: Lithium Industry - Tianqi Lithium (002466) saw an intraday increase of over 3%, while Ganfeng Lithium (002460) rose by 1.4%, as falling lithium prices may trigger localized supply contractions [5] Group 7: Gold Sector - Gold stocks generally declined, with Chifeng Jilong Gold Mining (600988) dropping over 2%, as gold prices fell below USD 3,300 [6] Group 8: Retail Sector - Tmall (06110) fell by over 9%, as institutions indicated that deepening discounts amid inventory reduction negatively impacted the company's gross margin performance [7]

Group 1: Hong Kong Stock Market - Nuclear power stocks strengthened, with China General Nuclear Power Corporation Mining rising over 8% and China General Nuclear Power Corporation increasing over 2% due to Trump's upcoming executive order aimed at simplifying reactor approval processes and strengthening fuel supply chains to promote the nuclear energy industry [1] - CRO concept stocks led the gains, as Trump's drug pricing policy is expected to benefit the domestic CXO industry, with institutions indicating a fundamental turning point has emerged; Zhaoyan New Drug surged over 11%, Tigermed rose over 10%, Kanglong Chemical increased over 6%, and WuXi AppTec gained 2% [1] - Gold stocks generally declined, with Chifeng Jilong Gold Mining and Shandong Gold falling over 3% as gold prices dropped below $3,300 [1] - Automotive stocks mostly rose, with Great Wall Motors increasing over 3%, BYD rising over 4%, Li Auto up over 4%, and Leap Motor gaining nearly 2%; the China Passenger Car Association expects retail sales of new energy vehicles to reach 980,000 units in May [1] - Country Garden saw a nearly 4% increase as over 70% of noteholders joined the restructuring support agreement [1] Group 2: US Stock Market - Vigil Neuroscience experienced a surge of over 241% following a premium acquisition by Sanofi, which announced it would acquire Vigil for $470 million in cash, potentially rising to $600 million based on future development milestones; the acquisition price represents a 236% premium over Vigil's closing price [2] - Sunrun, the largest rooftop solar company in the US, plummeted 37.05% due to the House of Representatives passing the "Beautiful Act," which significantly cuts green energy subsidies, leading to a sharp decline in the solar panel sector [2] - Fannie Mae and Freddie Mac stocks surged over 50% and 41%, respectively, following Trump's mention of privatization plans [2] - Nike's stock rose over 2% as the company plans to implement widespread price increases on products in the US market, expected to take effect as early as this week [2]

Group 1: Market Outlook - Morgan Stanley is optimistic about the Chinese stock market, with a baseline expectation for the MSCI China Index at 80 and a target for the CSI 300 Index at 4150 points [1] - UBS sees foreign capital inflow as a significant trading logic for the Chinese stock market in the coming quarters, with Hong Kong stocks expected to outperform A-shares [1] - Deutsche Bank analysts express concerns about fiscal balance in countries outside the US, highlighting Japan's low demand for 20-year bonds as a sign of fiscal stress [1] Group 2: Economic Indicators - Barclays analysts predict a potential further decline in the US dollar, but strong economic data may limit the extent of the drop [2] - ANZ analysts note that the downgrade of the US credit rating by Moody's has reignited interest in gold due to concerns over economic slowdown and rising inflation [3] - CBA forecasts gold prices to reach $3750 per ounce in Q4, driven by safe-haven demand and a weakening dollar [4] Group 3: Industry Insights - CICC reports that the domestic nutrition and health food industry has significant long-term growth potential, with a market size exceeding $35 billion [5] - CITIC Securities indicates that the pesticide industry in China is accelerating consolidation, with leading companies enhancing competitiveness through mergers and acquisitions [6] - CITIC Securities also highlights that the domestic wind turbine industry is expected to enter a phase of simultaneous growth in volume and price due to improved supply-demand dynamics [7]

这几只票暗盘资金正在偷偷流入，立即查看>> CRO概念板块短线拉升，河化股份（000953）涨停，金凯生科（301509）、睿智医药（300149）、诺 思格（301333）、昊帆生物（301393）、义翘神州（301047）等纷纷走高。 ...

板块涨幅居前的十大牛股分别是：阳光诺和（5.1%）、毕得医药（1.52%）、昭衍新药（0.88%）、药 康生物（0.85%）、诺泰生物（0.79%）、泓博医药（0.77%）、百诚医药（0.61%）、联化科技 （0.47%）、昊帆生物（0.45%）、泰格医药（0.4%）、美迪西（0.3%）、金凯生科（0.06%）、皓元医 药（0.05%）、迦南科技（0.0%）、睿智医药（0.0%）、太龙药业（-0.18%）、成都先导（-0.2%）、 义翘神州（-0.23%）、百花医药（-0.28%）、凯莱英（-0.33%） 本文源自：金融界 序代码股票名称现价涨跌幅主力资金净额主力资金净占比1300630普利退0.82-8.89-415.18 万-16.232301520万邦医药38.8-2.56-119.21万-1.503300759康龙化成22.41-2.52-2033.75万-4.674603739蔚 蓝生物13.6-1.73-655.01万-4.535603229奥翔药业8.13-1.69-488.23万-7.946000739普洛药业13.81- 1.642593.46万12.907688238和元生物5.71-1. ...

中邮证券表示，受益于海外投融资市场的率先复苏，需求端逐步恢复，CXO&上游公司订单增速提升， 行业拐点已过。CXO板块收入端恢复良好增长态势，盈利能力持续修复，利润端改善趋势更为显著， 基本面已呈现向上趋势。优质、高效、低成本的产品及服务为核心壁垒，我国制药业优势持续巩固，有 望在全球市场占据更高市场份额。中国创新药经过数十年发展，正在进入收获期，叠加政策友好性和市 场流动性提升，国内创新药市场前景光明。建议重点关注肿瘤、自免、减重、阿尔兹海默症、NASH、 脱发、乙肝等领域。 甬兴证券表示，百济神州凭借泽布替尼在欧美市场份额的提升保持收入规模的增长、恒瑞医药也多次实 现创新药的对外授权，我们认为国产创新药的竞争力正在持续提升，看好国产创新药的出海前景。 （本文机构观点来自持牌证券机构，不构成任何投资建议，亦不代表平台观点，请投资人独立判断和决 策。） 5月14日港股低开低走，医药生物板块逆市走强。热门ETF方面，港股创新药ETF（159567）盘中震荡 走高，截至发稿涨1.01%。换手率超7%，成交额快速突破1亿元，交投活跃。 成分股方面，三生制药涨超4%，康希诺生物、凯莱英涨超3%，晶泰控股、再鼎医药、科 ...